Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
OBJECTIVE
Prostate cancer is a disease of older men. Weekly docetaxel (DPq1w) is often favored over the standard three-weekly regimen (DPq3w) due to concerns about safety and tolerability in this population.


METHODS
Two subgroup analyses of TAX 327 were conducted. Among patients receiving DPq3w, tolerability and efficacy were compared between three age groups: <65, 65-74 and ≥75 years. For men ≥75 years, these outcomes were compared between DPq3w, DPq1w, and mitoxantrone (MP) arms. Tolerability outcomes included dose delivery, grade 3/4 adverse events and quality of life. Efficacy outcomes included overall survival and tumor response.


RESULTS
Of 1006 men with metastatic castrate-resistant prostate cancer (mCRPC) in the trial, 335 received DPq3w. Among these, 20% were age ≥75 years. For DPq3w, there were non-significant associations of worse tolerability and efficacy with advancing age. Twenty-eight percent of men age ≥75 years had an objective pain response, compared to 38% and 34% of patients 65-74 and <65 years, respectively. There were no significant differences in prostate-specific antigen (PSA) response (43-48%, p = 0.74) or measurable tumor response (7-17%, p = 0.30) according to age. Among men ≥75 years, DPq3w resulted in more dose reductions than DPq1w (22% versus 8%, p = 0.007), but tolerability was otherwise comparable. Both were associated with more favorable efficacy than mitoxantrone.


CONCLUSIONS
Tolerability and efficacy of DPq3w appear less favorable with advancing age. Compared to DPq1w, DPq3w is associated with better survival outcomes, but similar tolerability, and remains the standard first-line chemotherapy option in mCRPC. Toxicity is substantial, therefore careful patient selection, close monitoring and early management of toxicities is advised.
Department of Medical Oncology, Princess Margaret Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada; Department of Medical Oncology, Waterford Regional Hospital, Waterford, Ireland. Electronic address: annem.horgan@hse.ie.
Anne M
AM
Horgan
Sector of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.
Bostjan
B
Seruga
Department of Oncology and Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, Ontario, Canada.
Greg R
GR
Pond
Department of Medical Oncology, Princess Margaret Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
Shabbir M
SM
Alibhai
Department of Medical Oncology, Princess Margaret Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
Eitan
E
Amir
Department of Medical Oncology, Erasmus University Medical Center and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Ronald
R
De Wit
Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, United States.
Mario A
MA
Eisenberger
Department of Medical Oncology, Princess Margaret Hospital, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
Ian F
IF
Tannock
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D000077143:Docetaxel; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005853:Geriatrics; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D009367:Neoplasm Staging; D009919:Orchiectomy; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016019:Survival Analysis; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D043823:Taxoids; D000077143:Docetaxel; D008942:Mitoxantrone; D017430:Prostate-Specific Antigen
Docetaxel; Elderly; Prostate cancer